clonoSEQ
Commercial- Indications
- Blood cancers, Multiple myeloma, Diffuse large B-cell lymphoma
Company intelligence / Profile preview
Adaptive Biotechnologies
Seattle, Washington, United Statesadaptivebiotech.com ↗
- Ownership
- Public · ADPT
- Employees
- ~500
- Development stage
- Commercial
01
Overview
Adaptive’s clonoSEQ test for minimal residual disease (MRD) in blood cancers has been commercialized. The company’s platform supports both clinical diagnostics and research applications. It has a growing pipeline of diagnostic products leveraging its proprietary immune medicine platform. Clinical results have demonstrated high sensitivity in MRD detection for hematologic malignancies.
- Therapeutic areas
- HematologyImmunologyOncologyInfectious Diseases
- Modalities
- T-cell receptor (TCR) sequencingB-cell receptor (BCR) sequencingNGS-based diagnostics
- Industry
- Molecular Diagnostics
02
Drug pipeline
1 asset03
Partnerships
Microsoft (AI-driven diagnostics collaboration)Genentech/Roche (drug discovery partnership)NeoGenomics (expanding access to personalized blood cancer monitoring)
04
Financials
- Market cap
- $3.9B
- Total revenue
- $71.6M
- Enterprise value
- $4B
Beyond the preview
Go deeper on Adaptive Biotechnologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adaptive Biotechnologies.